CTOs on the Move

STRATEC Biomedical US

www.stratec.com

 
STRATEC Biomedical US is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.stratec.com
  • 3615 Old Conejo Rd
    Newbury Park, CA USA 91320
  • Phone: 805.728.1113

Executives

Name Title Contact Details

Similar Companies

Alba Therapeutics Corporation

Alba Therapeutics Corporation is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Alba Therapeutics Corporation is based in Baltimore, MD. You can find more information on Alba Therapeutics Corporation at www.albatherapeutics.com

DiagnosisONE Inc.

DiagnosisONE Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Passport Health Northeast Pennsylvania

Passport Health Northeast Pennsylvania is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nebraska Heart Institute

Nebraska Heart Institute is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.